Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report - Inserm - Institut national de la santé et de la recherche médicale
Article Dans Une Revue BMC Infectious Diseases Année : 2018

Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report

Résumé

Background: Hepatitis C virus (HCV) infection is a recognised cause of secondary immune thrombocytopenia (ITP). While its incidence has been largely described during chronic HCV infection, only one case of ITP secondary to acute HCV infection has been reported at this time. Case presentation: We report herein the case of severe ITP secondary to an acute HCV genotype 1a reinfection in a human immunodeficiency virus (HIV)-negative man having sex with men who had been cured several years before of a previous acute genotype 4d HCV infection. After an unsuccessful standard therapy with two courses of intravenous immunoglobulin (at 1 g/kg daily for 2 days) associated with methylprednisolone 1 mg/kg daily, antiviral treatment with sofosbuvir-ledipasvir rapidly achieved virological response and normalised the platelet count. Conclusions: As a direct effect of HCV on megakaryocytes could be the predominant cause of ITP during acute infection, early antiviral treatment may be beneficial in this case.
Fichier principal
Vignette du fichier
12879_2018_Article_3597.pdf (619.72 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

inserm-02043152 , version 1 (20-02-2019)

Identifiants

Citer

Vincent Alcazer, Patrick Miailhes, Christophe Ramière, Caroline Charre, Laurent Cotte. Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report. BMC Infectious Diseases, 2018, 18 (1), pp.682. ⟨10.1186/s12879-018-3597-4⟩. ⟨inserm-02043152⟩
125 Consultations
91 Téléchargements

Altmetric

Partager

More